- 裁员 28%。
- 停止对一半以上研究和技术项目的投资。查看全文
医药魔方2023-10-07 17:32
10月5日,基因疗法先驱uniQure宣布了一项战略性重组计划,以减少运营费用,并支持多个临床阶段项目的进展。
点击下载:细胞基因疗法研发全景解读
点击下载:“一步治愈式”基因疗法:短期利基市场?查看全文
chuminhua2023-10-06 14:36
10/5,战略重组将使 uniQure $uniQure(QURE)$ 停止一半以上的研究和技术项目,同时裁员 114 名员工,约占员工总数的 20%。 该公司周三宣布,由于产品线精简,首席科学官 Ricardo Dolmetsch 也将离职。
“经过广泛的审查,我们计划......将我们的研发工作重点放在利用我们的 CNS(中枢神经系统...查看全文
常青树学习巴菲特2023-05-28 12:52
$云顶新耀-B(01952)$ 全球最贵的药,以每剂350万美元的价格位居榜首的Hemgenix,是由CSL Behring和uniQure开发的一款基于腺相关病毒5(AAV5)的基因疗法,用于B型血友病患者。$腾讯控股(00700)$ $恒生指数(HKHSI)$查看全文
产业链观察2023-05-15 19:32
#药闻简讯# 2023年5月15日,为有严重医疗需求的患者提供变革性疗法的领先基因治疗公司$uniQure(QURE)$ 今天宣布它已达成一项最终协议,将CSL Behring从HEMGENIX®(etranacogene dezaparvovec-drbl)的净销售中应付给uniQure的部分版税权利出售给HealthCare Royalty(HCRx)和Sagard Hea...查看全文
SeekingBiotech2023-05-15 20:56
QURE Announces Sale of Royalty Interest in HEMGENIX.
uniQure to receive $375M upfront cash payment$uniQure(QURE)$
基因治疗,卖血友病权益。查看全文
淡投2015-02-12 02:02
Voyager Therapeutics & Genzyme Announce Major Strategic Collaboration to Develop and Commercialize Novel AAV Gene Therapies for Patients with CNS Disorders #基因治疗# $SPARK THERAPEUTICS INC(ONCE)$ $uniQure(QURE)$查看全文
淡投2015-02-11 15:46
$SPARK THERAPEUTICS INC(ONCE)$ is absolutely a competitor for $uniQure(QURE)$. It also uses AAV and has a pipeline that is certainly not superior to UniQure's. In my opinion, there is no reason UniQure should not have a market cap of around $1B at this time. The launch of...查看全文
淡投2015-02-11 02:28
网页链接 $百特(BAX)$ $SPARK THERAPEUTICS INC(ONCE)$ $uniQure(QURE)$ $BLUEBIRD BIO INC(BLUE)$ #血友病# #基因治疗#查看全文
an小安2014-11-27 22:36
$uniQure(QURE)$ 【世界上最贵的药物来了】名为"Glybera"的首款基因治疗药物将在德国上市,定价140万美元,用于治疗脂蛋白酯酶缺乏遗传病(LPLD)患者,由荷兰生物科技公司UniQure研发制造,天价的Glybera则展现了单一治疗如何修复缺陷基因,可能颠覆传统的医药商业模式。网页链接查看全文
littlebear1112014-02-07 01:44
$QURE(QURE)$ 第一支获批准的基因药物股,2013获全球top50创意企业,其卖的转基因药物高达160万欧元。@TigerinMotion 虎哥你觉得有潜力不?查看全文
智通财经APP获悉,H.C. Wainwright分析师Patrick Trucchio重申uniQure(QURE.US)“买入”评级,并给予目标价90美元。在辉瑞公司(PFE.US)公布了基因疗法fidanacogene elaparvovec用于治疗中重度至重度B型血友病的3期BENEGENE-2试验的主要... 网页链接
$uniQure(QURE)$ PRE 14A Other preliminary proxy statements Accession Number: 0001558370-24-004996 Act: 34 Size: 4 MB 网页链接
$uniQure(QURE)$ 8-K Current report, item 5.02 Accession Number: 0001558370-24-004994 Act: 34 Size: 145 KB 网页链接
$uniQure(QURE)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000904454-24-000203 Size: 7 KB 网页链接
$uniQure(QURE)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000904454-24-000199 Size: 7 KB 网页链接
$uniQure(QURE)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000904454-24-000201 Size: 7 KB 网页链接
$uniQure(QURE)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000904454-24-000197 Size: 7 KB 网页链接
$uniQure(QURE)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000904454-24-000195 Size: 7 KB 网页链接
$uniQure(QURE)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000904454-24-000191 Size: 5 KB 网页链接
$uniQure(QURE)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000904454-24-000189 Size: 5 KB 网页链接
$uniQure(QURE)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000904454-24-000187 Size: 5 KB 网页链接